Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Other Non-Current Assets (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Other Non-Current Assets data on record, last reported at $2.6 million in Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 1.48% year-over-year to $2.6 million; the TTM value through Dec 2025 reached $2.6 million, up 1.48%, while the annual FY2025 figure was $2.6 million, 1.48% up from the prior year.
  • Other Non-Current Assets reached $2.6 million in Q4 2025 per TARS's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $2.6 million in Q4 2025 and bottomed at $529000.0 in Q1 2023.
  • Average Other Non-Current Assets over 5 years is $1.2 million, with a median of $1.2 million recorded in 2025.
  • Peak YoY movement for Other Non-Current Assets: surged 1290.12% in 2021, then crashed 53.23% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $1.1 million in 2021, then crashed by 48.05% to $585000.0 in 2022, then surged by 114.19% to $1.3 million in 2023, then surged by 104.47% to $2.6 million in 2024, then rose by 1.48% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Other Non-Current Assets were $2.6 million in Q4 2025, $1.2 million in Q3 2025, and $1.2 million in Q2 2025.